Stay updated with breaking news from Ankur Vaid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
So we expect to do better than what we have done historically, which was a CAGR growth of 18%. And this as economies of scale would kick in once a new site starts ramping up, we see our margin profiling being better than what it has been historically, which has been in the range of around 40%.
Concord Biotech's grey market premium fell to 13-15 percent from 28 percent in the beginning of current month
Concord Biotech IPO | The main objective of the issue is to give a exit to Helix Investment Holdings which has 20 percent stake in the company.
Concord Biotech IPO | The issue comprises only an offer for sale (OFS) by Helix Investment Holdings Pte Limited, which is backed by Quadria Capital Fund LP, a healthcare-focused private equity fund in Asia.
According to the draft papers, healthcare-focused Asian private equity firm Quadria Capital also picked up a 20 percent stake in Concord Biotech in 2016